Examination of amylin expression in the islet during T1D progression reveals a disconnect from insulin expression during the late stages of the disease, suggesting that amylin may be used to detect an insulin-negative β-cell fraction that would otherwise go undetected by an insulin-based biomarker assay. The gene discussed is IAPP; the disease is type 1 diabetes mellitus.